Lowering Drug Costs for American Families Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Lowering Drug Costs for American Families Act (H.R. 4895) is a health policy bill introduced in the 118th Congress aimed at reducing prescription drug costs for American families. The bill was referred to the House Subcommittee on Health but did not advance further and ultimately failed or expired. Specific provisions, detailed text, and official summary are not available, limiting the ability to provide a detailed description of its mechanisms or scope.
H.R. 4895 sought to lower drug costs for Americans but did not progress beyond subcommittee referral and expired without enactment.
- The bill is focused on the health policy area, specifically targeting prescription drug costs.
- It was introduced in the House of Representatives during the 118th Congress.
- The bill was referred to the Subcommittee on Health on December 17, 2024, but did not advance and is now failed or expired.
['American families and individuals who pay for prescription drugs', 'Healthcare consumers seeking more affordable medication', 'Potentially healthcare providers and insurers if drug costs are reduced']
['Lack of available full bill text and official summary limits understanding of implementation details and cost implications.', 'Without legislative progress beyond referral, oversight and enforcement mechanisms are unclear.', 'Potential tradeoffs between drug pricing controls and pharmaceutical industry impacts cannot be assessed.']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. It did not advance further and expired, indicating limited legislative momentum. The policy area reflects ongoing congressional interest in addressing prescription drug affordability.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could influence pharmaceutical pricing strategies and insurance coverage policies.', 'Potential downstream effects on healthcare spending and patient access to medications might occur.', 'Legislative attention to drug costs may prompt further proposals or reforms in related health policy areas.']
Transparency is limited due to the absence of the full bill text and official summary, which restricts public and expert scrutiny. The bill's failure to advance beyond subcommittee referral suggests limited legislative support or prioritization during the 118th Congress. Monitoring similar future proposals will be important to assess evolving approaches to drug cost reduction.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.